Matches in Wikidata for { <http://www.wikidata.org/entity/Q90959689> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q90959689 description "article scientifique publié en 2019" @default.
- Q90959689 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90959689 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90959689 description "scientific article published on 26 October 2019" @default.
- Q90959689 description "wetenschappelijk artikel" @default.
- Q90959689 description "наукова стаття, опублікована 26 жовтня 2019" @default.
- Q90959689 name "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 name "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 type Item @default.
- Q90959689 label "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 label "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 prefLabel "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 prefLabel "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 P1433 Q90959689-23BAB91E-C41F-490C-8A83-A1E46BF5C938 @default.
- Q90959689 P1476 Q90959689-7AF16C03-76FF-4FF0-A3DE-0B41A35130D4 @default.
- Q90959689 P2093 Q90959689-0882475A-5DF0-427A-8902-0F3FEEE06BBB @default.
- Q90959689 P2093 Q90959689-80BF79D6-06BF-4B65-9755-1E3418712A9B @default.
- Q90959689 P2093 Q90959689-841942FE-86E6-4472-81D0-4AAEE157DD1A @default.
- Q90959689 P2093 Q90959689-91E86A54-93C0-4867-9676-CBECB3561FAD @default.
- Q90959689 P2093 Q90959689-94047F2F-8962-44F8-95B6-03EA1C9725CC @default.
- Q90959689 P2093 Q90959689-95B574E9-70B3-407F-B418-948153677E8E @default.
- Q90959689 P2093 Q90959689-9721B940-C188-45BD-B880-EC39E818357B @default.
- Q90959689 P2093 Q90959689-9B1CA45D-E684-472A-AF0D-3F8980E6168F @default.
- Q90959689 P2093 Q90959689-A1E2F9DB-D8A9-47B8-85E9-CB10F7552FFB @default.
- Q90959689 P2093 Q90959689-A566A504-1A29-4D56-B1BF-3264735A5C87 @default.
- Q90959689 P2093 Q90959689-ABA15683-A0ED-42BB-95E4-ECD1E93B2B8A @default.
- Q90959689 P2093 Q90959689-BCC799B4-9B8D-4ADF-B73C-EC09BB82DE5C @default.
- Q90959689 P2093 Q90959689-C5037B22-6E39-4FE3-9293-128EAE473A7E @default.
- Q90959689 P2093 Q90959689-CE02AFBD-D577-4A1B-A265-F93DC68841AA @default.
- Q90959689 P2093 Q90959689-E3F7D746-DD59-4831-AB4B-0557D3963C37 @default.
- Q90959689 P304 Q90959689-0905A118-0406-4254-98C8-5748BEEDACC6 @default.
- Q90959689 P31 Q90959689-2D76DD4B-8789-4FFF-9CB1-B266AB9A8E3F @default.
- Q90959689 P356 Q90959689-13C349B7-470B-41C2-B01B-3953BFA4E015 @default.
- Q90959689 P433 Q90959689-635B7F2E-276B-4B0D-B855-5B3ECDB5ADF3 @default.
- Q90959689 P478 Q90959689-2F339CFF-4E12-43A2-B448-23F0DD0E3F70 @default.
- Q90959689 P50 Q90959689-0F19D438-0DA5-422C-AB0E-A6185C3419ED @default.
- Q90959689 P50 Q90959689-5F8489A4-5968-419B-87F9-D434F22ED155 @default.
- Q90959689 P577 Q90959689-8C080030-DDA3-41D1-A323-8BD69696CF2E @default.
- Q90959689 P698 Q90959689-57DFC497-C1F4-4A01-B0B0-5BB88924B782 @default.
- Q90959689 P921 Q90959689-055C41AB-49BB-4718-ABB6-379C27287C3B @default.
- Q90959689 P921 Q90959689-BD3E5864-BF08-4EE4-A70B-3E85E1BDDD98 @default.
- Q90959689 P356 S11136-019-02296-5 @default.
- Q90959689 P698 31655974 @default.
- Q90959689 P1433 Q15749950 @default.
- Q90959689 P1476 "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis" @default.
- Q90959689 P2093 "Baojin Zhu" @default.
- Q90959689 P2093 "Carle Paul" @default.
- Q90959689 P2093 "Chen-Yen Lin" @default.
- Q90959689 P2093 "Darryl Toth" @default.
- Q90959689 P2093 "Emily Edson-Heredia" @default.
- Q90959689 P2093 "Enkeleida Nikaï" @default.
- Q90959689 P2093 "Hilde Carlier" @default.
- Q90959689 P2093 "Kenneth Gordon" @default.
- Q90959689 P2093 "Kristian Reich" @default.
- Q90959689 P2093 "Kristin Hollister" @default.
- Q90959689 P2093 "Matthias Augustin" @default.
- Q90959689 P2093 "Orin Goldblum" @default.
- Q90959689 P2093 "Richard B Warren" @default.
- Q90959689 P2093 "Richard G B Langley" @default.
- Q90959689 P2093 "Steven R Feldman" @default.
- Q90959689 P304 "369-380" @default.
- Q90959689 P31 Q13442814 @default.
- Q90959689 P356 "10.1007/S11136-019-02296-5" @default.
- Q90959689 P433 "2" @default.
- Q90959689 P478 "29" @default.
- Q90959689 P50 Q61138924 @default.
- Q90959689 P50 Q88283567 @default.
- Q90959689 P577 "2019-10-26T00:00:00Z" @default.
- Q90959689 P698 "31655974" @default.
- Q90959689 P921 Q10355321 @default.
- Q90959689 P921 Q42824827 @default.